FILGRASTIM
Ovarian Neoplasm
National Cancer Institute (NCI)protein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Ovarian Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vinorelbine AbbVie | Phase 3 | BB |
Sorafenib Bayer | Phase 2 | B |
(R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1,4,5,6,7,8-HEXAHYDRO-4AH-PYRAZOLO(3,4-G)ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE Corcept Therapeutics | Phase 3 | B |
Veliparib AbbVie | Phase 3 | B |
Ifa National Cancer Institute (NCI) | Phase 2 | CCC |
View all 15 →
Same molecule, other indications
FILGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →